Chain Drug Review - Novartis’ Diovan O.K.’d for a new use.(FDA approves Diovan)
EAST HANOVER, N.J. — The Food and Drug Administration has approved Diovan as a treatment for reducing cardiovascular deaths in patients who are at high risk after suffering a heart attack.
The regulatory agency granted Novartis Pharmaceuticals Corp. the expanded heart failure labeling for the product, which the company says has been the world’s most prescribed ARB (angiotensin receptor blocker).
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
Employee Incentive Program - Getting The Best Value For Money
“Millions of patients already rely on Diovan to help them to maintain healthier blood pressure goals,” notes Alex Gorsky, chief operating officer. “Now, based on …
Read the rest of this article with a Free Trial at HighBeam Research.
